None of the enrolled patients at enrollment had severe immunodeficiency (e.g., CD4 < 200 cells/mm3, or CD4 < 15%) or showed physical signs of such immunodeficiency, and all were on antiretroviral therapy. This evidence concerns the gene CD4 and immunodeficiency disease.